首页|基于组分合理性分析高血压复方药物

基于组分合理性分析高血压复方药物

Rationality of compound drug components against hypertension

扫码查看
目的 总结已上市的复方降压药并进行组分合理性分析,探讨其成分组成及疗效评估,为复方降压药的开发和创新提供参考.方法 检索国内外相关文献,对已上市的复方药物及批准的药物联合治疗方案进行分析和归纳.结果 复方降压药借助多种作用机制,显著改善药物依从性,降低心血管风险,并有效降低总体治疗成本.结论 复方降压药在治疗高血压中具有独特的优势,是治疗高血压和伴随疾病的更优选择,这将为复方药物的开发提供新的创新动力.
Objective To analyze the marketed combination antihypertensive drugs and the rationality of their components,explore their composition and assess their efficacy so as to provide references for the development and innovation of combination antihypertensive drugs.Methods The marketed compound drug combinations and approved drug combination therapy regimens were analyzed and summarized by searching domestic and foreign literature.Results With multiple mechanisms of action,compound antihypertensive drugs could improve drug compliance,reduce cardiovascular risks,and lower overall treatment cost.Conclusion Compound antihypertensive drugs have unique advantages in the treatment of hypertension.Compound drugs are also the best choice for the treatment of hypertension and concomitant diseases,which will provide a new impetus for the development of compound drugs in the future.

hypertensionantihypertensive drugscompound preparationsingle-pill combinationsdrug developmentcombination therapy

郭姝姝、江海燕、范潇予、李万芳、包捷、马恩龙、靳洪涛

展开 >

沈阳药科大学生命科学与生物制药学院,辽宁 沈阳 110016

中国医学科学院北京协和医学院药物研究所新药安全评价研究中心,北京 100050

北京协和建昊医药技术开发有限责任公司,北京 100176

国家药品监督管理局创新药物安全研究与评价重点实验室,北京 102206

展开 >

高血压 降压药 复方制剂 单片复方制剂 药物开发 联合治疗

国家自然科学基金资助项目中国毒理学会临床毒理课题

82074104CST2021CT101

2024

中国药物警戒
国家药品监督管理局药品评价中心(国家药品不良反应监测中心)

中国药物警戒

CSTPCD
影响因子:1.105
ISSN:1672-8629
年,卷(期):2024.21(9)